Product Information
IBUPROFEN 200 MG CAPLET is a generic product labeled by Major Pharmaceuticals, priced at $0.0331 per EA under NDC 00904791251. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 8, 1987.
Strength
200 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904791251
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA072096FDA Approved
12/8/1987
On Market Since
8/16/1994
Pharmacological Classes
Price Statistics
The NADAC for IBUPROFEN 200 MG CAPLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 21.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0331 per EA |
|---|---|
| All-time high | $0.0370 (Nov 12, 2025) |
| All-time low | $0.0250 (Jul 19, 2017) |
| 52-week high | $0.0370 |
| 52-week low | $0.0320 |
| Median price | $0.0322 |
| Average price | $0.0313 |
| Largest weekly change | -15.1% (Jul 19, 2017) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBUPROFEN 200 MG CAPLET?
The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN 200 MG CAPLET, manufactured by Major Pharmaceuticals, is $0.0331 per EA (NDC 00904791251), effective Sep 30, 2026.
How has the price of IBUPROFEN 200 MG CAPLET changed over time?
Over the history we have for it, the NADAC for IBUPROFEN 200 MG CAPLET has risen 21.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IBUPROFEN 200 MG CAPLET?
Since Nov 28, 2013, the NADAC for IBUPROFEN 200 MG CAPLET has ranged from a low of $0.0250 (Jul 19, 2017) to a high of $0.0370 (Nov 12, 2025), with a median of $0.0322 per EA.
Are there cheaper alternatives to IBUPROFEN 200 MG CAPLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN 200 MG TABLET, is $0.0269 per EA — about 19% below IBUPROFEN 200 MG CAPLET.
Who manufactures IBUPROFEN 200 MG CAPLET?
IBUPROFEN 200 MG CAPLET (NDC 00904791251) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.